[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 36471
86. Zecca G, Gradi EC, Nilsson K, Bellotti M, Dal Verme S, Vegni E, Moja EA: "All the rest is normal". A pilot study on the communication between physician and patient in prenatal diagnosis. J Psychosom Obstet Gynaecol; 2006 Sep;27(3):127-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "All the rest is normal". A pilot study on the communication between physician and patient in prenatal diagnosis.
  • The aim of the study was to verify in the context of prenatal diagnosis if the communicative style in consultations is modified in relation to the seriousness of the diagnosis.
  • The communication during the consultation seems to be mostly influenced by a highly disease-centered model that is not dependent on the content of the consultation itself.
  • Only emotional exchanges showed a marginally significant decrease in the H visits (t = 1.995, p = 0.057), suggesting the probable difficulty of the disease-centered model to manage emotional items during a highly dramatic consultation.
  • [MeSH-major] Communication. Fetal Diseases / diagnosis. Fetal Diseases / psychology. Physician-Patient Relations. Prenatal Diagnosis / psychology


87. Murphy AJ, Wells JC, Williams JE, Fewtrell MS, Davies PS, Webb DK: Body composition in children in remission from acute lymphoblastic leukemia. Am J Clin Nutr; 2006 Jan;83(1):70-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition in children in remission from acute lymphoblastic leukemia.
  • BACKGROUND: Changes in body composition are commonly reported in pediatric survivors of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Adipose Tissue / metabolism. Body Composition. Body Water / metabolism. Muscle, Skeletal / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. DEUTERIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400052.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; AR09D82C7G / Deuterium
  •  go-up   go-down


88. Arhan E, Kaya Z, Serdaroğlu A, Ozcelik AA, Bilir E, Durdağ E, Kurt G, Albayrak M: Successful surgical treatment of medically refractory epilepsy after chemotherapy in a child with leukemia: a case report. Neurologist; 2010 Jan;16(1):41-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful surgical treatment of medically refractory epilepsy after chemotherapy in a child with leukemia: a case report.
  • INTRODUCTION: Mesial temporal sclerosis associated with acute lymphoblastic leukemia has been rarely reported.
  • CASE REPORT: We report a case of a 15-year-old boy with acute lymphoblastic leukemia who developed medically refractory temporal lobe epilepsy in a long time period after chemotherapy, and successfully treated with surgical resection.
  • [MeSH-major] Epilepsy / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065796.001).
  • [ISSN] 2331-2637
  • [Journal-full-title] The neurologist
  • [ISO-abbreviation] Neurologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents
  •  go-up   go-down


89. Archangelo LF, Gläsner J, Krause A, Bohlander SK: The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10. Oncogene; 2006 Jul 6;25(29):4099-109
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Clathrin Assembly Lymphoid Myeloid leukemia gene (CALM or PICALM) was first identified as the fusion partner of AF10 in the t(10;11)(p13;q14) translocation, which is observed in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and malignant lymphoma.
  • The interaction between CALM and CATS could be confirmed using pull down assays, co-immunoprecipitation and colocalization experiments.
  • [MeSH-major] Active Transport, Cell Nucleus. Carrier Proteins / metabolism. Cell Nucleolus / metabolism. Monomeric Clathrin Assembly Proteins / metabolism. Oncogene Proteins, Fusion / metabolism
  • [MeSH-minor] 3T3 Cells. Animals. Base Sequence. Cell Transformation, Neoplastic / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 10 / metabolism. Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 13 / metabolism. Gene Expression Regulation / genetics. Humans. Mice. Molecular Sequence Data. Organ Specificity. Protein Binding / genetics. Translocation, Genetic / genetics

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16491119.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AF10-CALM fusion protein, human; 0 / Carrier Proteins; 0 / FAM64A protein, human; 0 / Monomeric Clathrin Assembly Proteins; 0 / Oncogene Proteins, Fusion; 0 / PICALM protein, human
  •  go-up   go-down


90. Yang HK, Yu HG: Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease. Korean J Ophthalmol; 2009 Dec;23(4):325-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease.
  • We describe a case of bilateral exudative retinal detachment associated with prodromal symptoms simulating the presentation of acute Vogt-Koyanagi-Harada disease that was eventually diagnosed as acute lymphoblastic leukemia.
  • A clinical diagnosis of incomplete type Vogt-Koyanagi-Harada disease was considered.
  • However, complete blood cell count showed a marked increase in the number of white blood cells and bone marrow examination revealed precursor B cell lymphoblastic leukemia.
  • Bilateral exudative retinal detachment associated with neurologic and auditory abnormalities may be a presenting sign of acute lymphoblastic leukemia.
  • Clinicians should be aware of the possibility of leukemia in such patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Detachment / etiology. Uveomeningoencephalitic Syndrome / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fluorescein Angiography. Follow-Up Studies. Fundus Oculi. Humans. Male. Tomography, Optical Coherence. Visual Acuity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kaohsiung J Med Sci. 2001 Mar;17(3):150-5 [11486647.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):691-9 [12447107.001]
  • [Cites] Leuk Res. 2003 Jun;27(6):557-9 [12648516.001]
  • [Cites] Am J Ophthalmol. 1979 May;87(5):698-702 [443342.001]
  • [Cites] Ann Ophthalmol. 1979 Dec;11(12):1867-72 [299244.001]
  • [Cites] Am J Ophthalmol. 1987 Oct 15;104(4):364-72 [3661646.001]
  • [Cites] Retina. 1989;9(2):110-4 [2772418.001]
  • [Cites] Am J Ophthalmol. 1990 Apr 15;109(4):436-44 [2330946.001]
  • [Cites] Am J Ophthalmol. 1996 Jul;122(1):58-66 [8659599.001]
  • [Cites] Surv Ophthalmol. 1964 Oct;9:467-73 [14199728.001]
  • [Cites] Eur J Ophthalmol. 2005 Mar-Apr;15(2):284-6 [15812775.001]
  • [Cites] Retina. 2006 Jul-Aug;26(6):710-2 [16829822.001]
  • [Cites] Am J Ophthalmol. 2007 Aug;144(2):260-5 [17533104.001]
  • [Cites] Curr Eye Res. 2008 Jul;33(7):517-23 [18600484.001]
  • [Cites] Retina. 2003 Dec;23(6):820-46; quiz 895-6 [14707834.001]
  • [Cites] Acta Haematol. 2000;104(1):46-9 [11111123.001]
  • [Cites] Am J Ophthalmol. 2001 May;131(5):647-52 [11336942.001]
  • [Cites] Retina. 2001;21(3):237-42 [11421013.001]
  • (PMID = 20046700.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2789964
  • [Keywords] NOTNLM ; Exudative retinal detachment / Leukemia / Vogt-Koyanagi-Harada disease
  •  go-up   go-down


91. Beverland D: Patient satisfaction following TKA: Bless them all! Orthopedics; 2010 Sep;33(9):657
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient satisfaction following TKA: Bless them all!
  • Survivorship following modern total knee arthroplasty (TKA) is good with revision rates generally lower than for total hip arthroplasty (THA).
  • Our experience in Belfast supports that fact with original component survivorship of 99% for the low contact stress rotating platform TKA, which is better than our THA survivorship.
  • It is important to discriminate between survivorship and patient satisfaction.
  • In Belfast, as well as the more familiar outcome scores, we also use a very simple 4-point satisfaction questionnaire: "How would you best describe your satisfaction with your new joint" where 1=very happy, 2=happy, 3=OK but not perfect, and 4=I have never been happy.
  • We applied this questionnaire to our 10-year THA and TKA patients.
  • When we looked specifically at the numbers of patients who were either "very happy" or "never happy," the results were very different.
  • The very happy percentage for hips was much higher than for knees (54% vs 4%) and conversely, the number of never happy knees was much higher than for hips (7% vs 1%).
  • These results are not unique to Belfast.
  • As surgeons, we often think that the knee implant that we use is the best but at present, the implant is no longer the most critical factor.
  • We need to increase the number of very happy patients and decrease the number of never happy ones.
  • In my opinion the two key factors that we should focus on are patient expectation and surgeon education.
  • [MeSH-major] Arthroplasty, Replacement, Knee. Patient Satisfaction
  • [MeSH-minor] Arthroplasty, Replacement, Hip. Cohort Studies. Follow-Up Studies. Humans. Orthopedics / education. Patient Education as Topic. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • (PMID = 20839698.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Roy C: [Imaging of urinary lithiasis: "all in one"]. Ann Urol (Paris); 2006 Apr;40(2):69-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Imagerie de la lithiase urinaire: "Trois en un".
  • Helical CToperated with newer devices is the most accurate modality to provide all needed information: diagnosis of stone without contrast medium injection, morphology (size, number) and localization, diagnosis of urinary obstruction, urinary tract aspect and all kind of differential diagnosis in emergency.
  • Multiplanar reconstructions are essential for the clinicians; but diagnosis is interpreted by scrolling axial views with dynamic analysis on computer screen.
  • [MeSH-major] Urinary Calculi / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709006.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 69
  •  go-up   go-down


93. Meng CQ: Atherosclerosis is an inflammatory disorder after all. Curr Top Med Chem; 2006;6(2):93-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atherosclerosis is an inflammatory disorder after all.
  • Accumulating evidence has led to the conclusion that atherosclerosis is an inflammatory disease, although it was believed to be a disorder of high cholesterol levels in the bloodstream for over a century.
  • Statins lower cholesterol levels and hence reduce inflammation in the vasculature and prevent heart disease.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454761.001).
  • [ISSN] 1568-0266
  • [Journal-full-title] Current topics in medicinal chemistry
  • [ISO-abbreviation] Curr Top Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents
  • [Number-of-references] 89
  •  go-up   go-down


9
Advertisement
4. Nagano A, Komura T, Yoshioka S, Fukashiro S: Contribution of non-extensor muscles of the leg to maximal-effort countermovement jumping. Biomed Eng Online; 2005;4:52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of non-extensor muscles of the leg to maximal-effort countermovement jumping.
  • BACKGROUND: The purpose of this study was to determine the effects of non-extensor muscles of the leg (i.e., muscles whose primary function is not leg extension) on the kinematics and kinetics of human maximal-effort countermovement jumping.
  • Although it is difficult to address this type of question through experimental procedures, the methodology of computer simulation can be a powerful tool.
  • METHODS: A skeletal model that has nine rigid body segments and twenty degrees of freedom was developed.
  • Two sets of muscle models were attached to this skeletal model: all (most of) major muscles in the leg ("All Muscles" model) and major extensor muscles in the leg (i.e., muscles whose primary function is leg extension; "Extensors Only" model).
  • Neural activation input signal was represented by a series of step functions with a step duration of 0.05 s.
  • Simulations were started from an identical upright standing posture.
  • The optimal pattern of the activation input signal was searched through extensive random-search numerical optimization with a goal of maximizing the height reached by the mass centre of the body after jumping up.
  • RESULTS: The simulated kinematics was almost two-dimensional, suggesting the validity of two-dimensional analyses when evaluating net mechanical outputs around the joints using inverse dynamics.
  • A greater jumping height was obtained for the "All Muscles" model (0.386 m) than for the "Extensors Only" model (0.301 m).
  • For the "All Muscles" model, flexor muscles developed force in the beginning of the countermovement.
  • For the "All Muscles" model, the sum of the work outputs from non-extensor muscles was 47.0 J, which was 13% of the total amount (359.9 J).
  • The quantitative distribution of the work outputs from individual muscles was markedly different between these two models.
  • CONCLUSION: It was suggested that the contribution of non-extensor muscles in maximal-effort countermovement jumping is substantial.
  • The use of a computer simulation model that includes non-extensor muscles seems to be more desirable for the assessment of muscular outputs during jumping.
  • [MeSH-major] Joints / physiology. Leg / physiology. Movement / physiology. Muscle Contraction / physiology. Muscle, Skeletal / physiology. Physical Exertion / physiology. Postural Balance / physiology
  • [MeSH-minor] Computer Simulation. Humans. Models, Biological. Motor Skills / physiology. Physical Endurance / physiology. Task Performance and Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomech Eng. 1982 Nov;104(4):304-10 [7154650.001]
  • [Cites] J Biomech. 1990;23(1):91-5 [2307696.001]
  • [Cites] IEEE Trans Biomed Eng. 1990 Aug;37(8):757-67 [2210784.001]
  • [Cites] J Biomech. 1990;23(12):1185-98 [2292598.001]
  • [Cites] J Biomech. 1991;24(1):1-10 [2026629.001]
  • [Cites] J Biomech. 1993 Jan;26(1):1-8 [8423165.001]
  • [Cites] J Electromyogr Kinesiol. 2005 Aug;15(4):367-76 [15811607.001]
  • [Cites] Med Sci Sports Exerc. 1994 Aug;26(8):1012-20 [7968418.001]
  • [Cites] Eur J Appl Physiol Occup Physiol. 1995;71(5):453-8 [8565978.001]
  • [Cites] J Biomech. 1996 Sep;29(9):1223-30 [8872282.001]
  • [Cites] Med Sci Sports Exerc. 1996 Nov;28(11):1402-12 [8933491.001]
  • [Cites] Exp Brain Res. 1998 Jul;121(1):76-91 [9698193.001]
  • [Cites] Am J Phys Anthropol. 2005 Jan;126(1):2-13 [15386246.001]
  • [Cites] J Biomech. 1993 Dec;26(12):1413-27 [8308046.001]
  • (PMID = 16143047.001).
  • [ISSN] 1475-925X
  • [Journal-full-title] Biomedical engineering online
  • [ISO-abbreviation] Biomed Eng Online
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1215494
  •  go-up   go-down


95. Kager L: Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia. J BUON; 2009 Sep;14 Suppl 1:S181-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia.
  • Childhood acute lymphoblastic leukemia (ALL) is the classic example for a drug-responsive malignancy, and contemporary risk-directed therapies cure more than 80% of children with ALL in industrialized countries.
  • Moreover, some children have leukemia cell clones which are resistant to current antileukemic treatment.
  • As ALL is still among the leading causes of death from disease in children aged one to 15 years, further improvement of childhood ALL therapy is urgently needed.
  • [MeSH-major] Pharmacogenetics / methods. Precision Medicine / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


96. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J: Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood; 2010 Jul 1;115(26):5428-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Mutation / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein Kinase Inhibitors / therapeutic use


97. Lancioni C, LaBeaud AD, Esper F, Abughali N, Auletta J: Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Dec 15;53(7):1318-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia.
  • In this report we describe a case of primary pulmonary tuberculosis (TB) in a boy with precursor B-cell acute lymphoblastic leukemia (ALL) and review the pertinent literature.
  • [MeSH-major] Fever of Unknown Origin / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Tuberculosis, Pulmonary / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Tuberculosis.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. ISONIAZID .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ETHAMBUTOL .
  • Hazardous Substances Data Bank. AZITHROMYCIN .
  • Hazardous Substances Data Bank. PYRAZINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19618457.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents; 04079A1RDZ / Cytarabine; 2KNI5N06TI / Pyrazinamide; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 83905-01-5 / Azithromycin; 8G167061QZ / Ethambutol; 8N3DW7272P / Cyclophosphamide; V83O1VOZ8L / Isoniazid; VJT6J7R4TR / Rifampin
  •  go-up   go-down


98. Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group: Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol; 2008 Nov;143(4):503-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
  • The clinical significance of minimal residual disease (MRD) is uncertain in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) treated with imatinib-combined chemotherapy.
  • Of these, 10 of the 16 who had undergone allogeneic haematopoietic stem cell transplantation (HSCT) in first CR were alive without relapse at a median of 2.9 years after transplantation, whereas 12 of the 13 who had not undergone allogeneic HSCT experienced a relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Fusion Proteins, bcr-abl / analysis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Adolescent. Adult. Benzamides. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm, Residual. Piperazines / administration & dosage. Prognosis. Prospective Studies. Pyrimidines / administration & dosage. Recurrence. Reverse Transcriptase Polymerase Chain Reaction / methods. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Sep;146(5):576-7 [19555375.001]
  • (PMID = 18986386.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


99. Kager L, Evans WE: Pharmacogenomics of acute lymphoblastic leukemia. Curr Opin Hematol; 2006 Jul;13(4):260-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenomics of acute lymphoblastic leukemia.
  • PURPOSE OF REVIEW: The cure rate in children with acute lymphoblastic leukemia now exceeds almost 80% in most treatment protocols in industrialized countries.
  • Pharmacogenomics, which studies the role of inheritance in individual variation in drug disposition and response, could be a useful tool to further improve outcome in this heterogeneous disease by individualization of therapy based on information gained from the genetic 'make-up' of normal host cells and lymphoblastic leukemia cells.
  • Thus there is great promise for advancing event-free survival in childhood leukemia in the future.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pharmacogenetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Disease-Free Survival. Humans. Randomized Controlled Trials as Topic. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755223.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 49
  •  go-up   go-down


100. Mitchell C, Richards S, Harrison CJ, Eden T: Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia; 2010 Feb;24(2):406-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001.
  • Between 1980 and 2001, the United Kingdom Medical Research Council Childhood Leukemia Working Party conducted four clinical trials in acute lymphoblastic leukaemia (ALL), which recruited a total of 6516 patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] Br J Haematol. 2009 Aug;146(4):424-36 [19549269.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2307-20 [11187922.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):3-10 [11328273.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):445-55 [12139731.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1798-809 [12721257.001]
  • [Cites] J Clin Oncol. 1983 May;1(5):317-25 [6366138.001]
  • [Cites] Arch Dis Child. 1985 Nov;60(11):1050-4 [3907505.001]
  • [Cites] Lancet. 1986 Feb 22;1(8478):408-11 [2868339.001]
  • [Cites] Med Pediatr Oncol. 1986;14(3):189-90 [3462466.001]
  • [Cites] Arch Dis Child. 1987 Jan;62(1):12-8 [3468886.001]
  • [Cites] Med Pediatr Oncol. 1990;18(6):497-502 [2233523.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] Br J Haematol. 1991 Jun;78(2):187-96 [2064956.001]
  • [Cites] Lancet. 1992 Sep 5;340(8819):565-8 [1355153.001]
  • [Cites] Br J Haematol. 1992 May;81(1):52-7 [1520624.001]
  • [Cites] Lancet. 1995 Jan 21;345(8943):143-8 [7823668.001]
  • [Cites] Br J Haematol. 1995 Feb;89(2):364-72 [7873387.001]
  • [Cites] Lancet. 1996 Jun 29;347(9018):1783-8 [8667921.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):603-6 [9207407.001]
  • [Cites] Br J Haematol. 1997 Sep;98(4):945-51 [9326194.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):93-100 [9359508.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1249-55 [9697880.001]
  • [Cites] Br J Haematol. 2005 May;129(4):520-30 [15877734.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1339-48 [17046466.001]
  • [Cites] Br J Haematol. 2009 May;145(3):376-88 [19236609.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • (PMID = 20010621.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G8223452(65788); United Kingdom / Medical Research Council / / MC/ U137686856; United Kingdom / Medical Research Council / / G8223452
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2820452; NLM/ UKMS28094
  •  go-up   go-down






Advertisement